Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.74, $0.44 better than the analyst estimate of $0.30. Revenue for the quarter came in at $155.1 million versus the consensus estimate of $130.66 million.

• Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 million
• Q3 2020 operating earnings of $56.1 million
• On track to initiate commercial launch of SPN-812 in January 2021, if approved by the FDA
• Topline data from the SPN-812 Phase III trial in adult ADHD patients expected in Q1 2021
• Submitted SPN-830 (Apomorphine infusion pump) NDA to the FDA in September 2020
• Increased full year 2020 net product sales guidance range of $500 million to $525 million, and operating earnings guidance range of $145 million to $160 million

“During the first nine months of 2020, we delivered strong product sales growth, diversified our revenue base and enhanced our long term growth with two corporate transactions” said Jack Khattar, President and CEO of Supernus. “Our employees have been hard at work in anticipation of the launch of SPN-812. Based on the efficacy and safety demonstrated in its clinical program, SPN-812 can potentially offer an important new option in the treatment of ADHD.”

GUIDANCE:

Supernus Pharma sees FY2020 revenue of $500-525 million, versus the consensus of $486.54 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.